AbbVie
1 North Waukegan Road
North Chicago
Illinois
60064
United States
Tel: 1-800-255-5162
Website: http://www.abbvie.com/
Email: customerservice@abbvie.com
About AbbVie
AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook or LinkedIn.
Stock Symbol: ABBV
Stock Exchange: NYSE
People. Passion. Possibilities. Those three simple words mean everything at AbbVie, where patients always come first. So do cutting-edge science and innovation, which fuel our expanding pipeline as we take on the world's toughest health challenges in oncology, immunology, liver disease, women's health and beyond. Together, we strive to make a difference for patients around the world. For more visit: www.abbvie.com.
931 articles with AbbVie
-
Seven pharma executives will enter the Congressional crucible next week as they face questions and concerns over the rising costs of prescription drugs.
-
It’s nice to be admired. Fortune released its list of the most respected companies across the globe and one pharma company made the top 50 list.
-
AbbVie Announces New Drug Application Accepted for Priority Review by U.S. FDA for Upadacitinib for Treatment of Moderate to Severe Rheumatoid Arthritis
2/19/2019
Upadacitinib, an investigational once-daily oral JAK1-selective inhibitor, is being studied for the treatment of adult patients with moderate to severe rheumatoid arthritis
-
Lawmakers continue to hear concerns over drug prices, as well as proposals to fix the issue.
-
AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma
2/11/2019
AbbVie, Teneobio, Inc. and its affiliate TeneoOne, Inc. announced that they have entered a global strategic transaction to develop and commercialize TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of multiple myeloma.
-
BioArctic: U.S. Food and Drug Administration Approves Investigational New Drug Applicationfor ABBV-0805
2/11/2019
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that AbbVie has received approval from the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for ABBV-0805.
-
AbbVie is taking a $90 million plunge into B-cell maturation antigen (BCMA)-targeting immunotherapeutics against multiple myeloma in a collaborative deal with Menlo Park, Calif.-based Teneobio, Inc.
-
Johnson Fistel, LLP Announces Investigations of AbbVie Inc., Macquarie Infrastructure Corporation, OPKO Health, Inc. and Uxin Limited; Investors Encouraged to Contact Firm
2/5/2019
Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims.
-
According to a BioSpace Community Survey, almost 70% of life sciences professionals plan to look for a new job in the next 12 months. Don't delay, accelerate your job search and check out top companies who are looking for quality candidates in 2019!
-
IDEA Pharma recently published its “Pharmaceutical Innovation Index 2018.” This report ranks biopharma companies on their ability to bring products from Phase I/II to market and then successfully commercialize them. They used a variety of sources, including company websites, third-party instituti...
-
Q4 Biopharma Themes: Strong 2018, Weaker 2019 Earnings Projections, Concerns Over Drug Pricing
2/1/2019
Many of the big biopharma companies reported fourth-quarter and year-end earnings this week. If there’s a theme among them, it seems lower earnings per share are forecast for the year. -
AbbVie Announces U.S. FDA Approval of IMBRUVICA® (ibrutinib) Plus Obinutuzumab (GAZYVA®)
1/28/2019
First Chemotherapy-Free, Anti-CD20 Combination Regimen Approved for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) in Previously Untreated Patients
-
AbbVie Announces U.S. FDA Approval of IMBRUVICA® (ibrutinib) Plus Obinutuzumab (GAZYVA®) - First Chemotherapy-Free, Anti-CD20 Combination Regimen Approved for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
1/28/2019
FDA approval is based on positive Phase 3 iLLUMINATE (PCYC-1130) study results, which demonstrated IMBRUVICA plus obinutuzumab significantly prolonged progression-free survival versus the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines Category 1 treatment of chlorambucil plus obinutuzumab
-
The approval of the combination marks a first for the U.S. market. The combination of AbbVie and Janssen’s Imbruvica with Roche’s Gazyva is the first chemotherapy-free, anti-CD20 combination to treat CLL and SLL patients who have not yet started therapy, AbbVie said this morning.
-
AbbVie Reports Full-Year and Fourth-Quarter 2018 Financial Results
1/25/2019
Reports Full-Year Diluted EPS of $3.66 on a GAAP Basis; Adjusted Diluted EPS of $7.91 Reflects Growth of 41.3 Percent
-
AbbVie reported a loss of $1.83 billion for the fourth quarter of 2018. Overall revenues were up for the full year, however, hitting $32.75 billion compared to $28.2 billion in 2017.
-
The company provided an update on its Phase III trial of Imbruvica in combination with chemotherapy compared to placebo in metastatic pancreatic adenocarcinoma.
-
AbbVie Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA®) in Metastatic Pancreatic Cancer
1/18/2019
The RESOLVE (PCYC-1137) trial evaluated ibrutinib in combination with chemotherapy agents nab-paclitaxel and gemcitabine versus placebo in combination with these chemotherapy agents
-
In 2018, the FDA approved 59 novel drugs, meaning approved new molecular entities. BioSpace analyzed new drug approvals from 2014 to 2018 to determine which companies were responsible for the most drug approvals in that period. Here’s a look.
-
New Year, fresh start? Could be. WalletHub recently compared more than 180 cities across the U.S., using 30 key indicators to evaluate their job strength. Some of those factors were job opportunities, employment growth, monthly average starting salary and employment outlook.